Fiasp Flextouch is a drug owned by Novo Nordisk Inc. It is protected by 20 US drug patents filed from 2018 to 2019. Out of these, 15 drug patents are active and 5 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 01, 2032. Details of Fiasp Flextouch's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9132239 | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | Active |
| US8324157 | Preparation comprising insulin, nicotinamide and an amino acid |
Jun, 2030
(5 years from now) | Active |
| US9687611 | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | Active |
| USRE46363 | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 8 months from now) | Active |
| US7686786 | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 8 months from now) | Active |
| US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 7 months from now) | Active |
| US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 7 months from now) | Active |
| US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 7 months from now) | Active |
| US9457154 | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | Active |
| US10376652 | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | Active |
| US9616180 | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | Active |
| US9108002 | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | Active |
| US10357616 | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | Active |
| US9861757 | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | Active |
| US8684969 | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | Active |
| US7762994 | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(5 months ago) |
Expired
|
| US8579869 | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(1 year, 4 months ago) |
Expired
|
| US9486588 | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) |
Expired
|
| US8672898 | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) |
Expired
|
| US6899699 | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fiasp Flextouch's patents.
Latest Legal Activities on Fiasp Flextouch's Patents
Given below is the list of recent legal activities going on the following patents of Fiasp Flextouch.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed Critical | 01 Jul, 2024 | US9486588 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 May, 2024 | US8324157 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2024 | US9457154 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Feb, 2023 | US9132239 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Jan, 2023 | US9108002 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Jan, 2023 | US10376652 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Dec, 2022 | US10357616 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Aug, 2022 | US10220155 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 May, 2022 | US8920383 |
| Expire Patent Critical | 02 May, 2022 | US7686786 |
FDA has granted several exclusivities to Fiasp Flextouch. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Fiasp Flextouch, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Fiasp Flextouch.
Exclusivity Information
Fiasp Flextouch holds 2 exclusivities. All of its exclusivities have expired in 2022. Details of Fiasp Flextouch's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 29, 2020 |
| New Patient Population(NPP) | Dec 19, 2022 |
Several oppositions have been filed on Fiasp Flextouch's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Fiasp Flextouch's generic, the next section provides detailed information on ongoing and past EP oppositions related to Fiasp Flextouch patents.
Fiasp Flextouch's Oppositions Filed in EPO
Fiasp Flextouch has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 23, 2006, by Owen Mumford Limited. This opposition was filed on patent number EP02726984A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP02726984A | NA | Genentech, Inc. | Patent maintained as amended |
| EP06701034A | Jan, 2018 | Schwöbel, Thilo | Opposition rejected |
| EP06754730A | Dec, 2011 | Ypsomed AG | Patent maintained as amended |
| EP06754730A | Nov, 2011 | WMC Matthes Consulting | Patent maintained as amended |
| EP06762643A | Jul, 2010 | Sanofi-Aventis Deutschland GmbH | Patent maintained as amended |
| EP05796880A | Jul, 2010 | Stöckeler, Ferdinand | Granted and Under Opposition |
| EP05796880A | Jul, 2010 | Ypsomed AG | Granted and Under Opposition |
| EP05796880A | Jul, 2010 | Ferring International Center S.A. | Granted and Under Opposition |
| EP05796880A | Jul, 2010 | OWEN MUMFORD LIMITED | Granted and Under Opposition |
| EP05796880A | Jul, 2010 | Genentech, Inc. | Granted and Under Opposition |
| EP05796880A | Jul, 2010 | COPERNICUS sp. zo.o. | Granted and Under Opposition |
| EP06121820A | May, 2010 | SANOFI-AVENTIS DEUTSCHLAND GMBH | Opposition rejected |
| EP02726984A | Mar, 2006 | TecPharma Licensing AG | Patent maintained as amended |
| EP02726984A | Feb, 2006 | OWEN MUMFORD LIMITED | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Fiasp Flextouch is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fiasp Flextouch's family patents as well as insights into ongoing legal events on those patents.
Fiasp Flextouch's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Fiasp Flextouch's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 01, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Fiasp Flextouch Generics:
There are no approved generic versions for Fiasp Flextouch as of now.
Alternative Brands for Fiasp Flextouch
Fiasp Flextouch which is used for managing symptoms of depression and anxiety disorders., has several other brand drugs using the same active ingredient (Insulin Aspart). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Novo |
| |||||||||
| Novo Nordisk Inc |
|
About Fiasp Flextouch
Fiasp Flextouch is a drug owned by Novo Nordisk Inc. It is used for managing symptoms of depression and anxiety disorders. Fiasp Flextouch uses Insulin Aspart as an active ingredient. Fiasp Flextouch was launched by Novo in 2017.
Approval Date:
Fiasp Flextouch was approved by FDA for market use on 29 September, 2017.
Active Ingredient:
Fiasp Flextouch uses Insulin Aspart as the active ingredient. Check out other Drugs and Companies using Insulin Aspart ingredient
Treatment:
Fiasp Flextouch is used for managing symptoms of depression and anxiety disorders.
Dosage:
Fiasp Flextouch is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 300 UNITS/3ML (100 UNITS/ML) | SOLUTION | Prescription | SUBCUTANEOUS |